Myriad's Prolaris(R) Test Guides Treatment Decisions For Men With Prostate Cancer

SALT LAKE CITY, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will present data from four clinical studies with Prolaris at the 14 th Annual Meeting of the Society for Urologic Oncology (SUO) in Bethesda, Md. Prolaris is a prognostic test that accurately predicts cancer-specific disease progression and mortality based on an analysis of 46 cell cycle progression genes. The Prolaris score has been demonstrated to be a stronger predictor of prostate cancer recurrence and cancer-specific death than clinical parameters such as Gleason score and PSA. 

In addition to compelling data on the clinical utility of Prolaris in changing treatment plans for men with prostate cancer, the Company will present data from two new clinical studies on the Prolaris test. These studies further demonstrate the ability of the Prolaris test to accurately stratify a prostate cancer patient's risk of having an aggressive form of the disease. Prolaris has now been validated in 11 clinical studies in approximately 5,000 patients with prostate cancer. Another new study in renal cell carcinoma also will be presented at the SUO meeting, demonstrating that Myriad's cell cycle progression gene panel predicts metastatic progression in patients with this deadly cancer.

"A major challenge for physicians treating men with prostate cancer is knowing whether a prostatectomy or other type of treatment is necessary, or if active surveillance is appropriate," said Michael Brawer, M.D. vice president of Medical Affairs at Myriad Genetic Laboratories. "Our data demonstrate the utility of Prolaris in helping physicians determine the most appropriate and effective treatment for each individual patient based on the aggressiveness of their cancer."

Clinical Utility of Cell Cycle Progression Genes in Facilitating Prostate Cancer Treatment Decisions. [Shore et al., Poster Session II: Dec. 6, 2013, 4:30 p.m. ET]

The prostate biopsy research study evaluated Prolaris' potential clinical utility in guiding the treatment decision for patients diagnosed with prostate cancer. Participating physicians were asked to assess the value of the Prolaris score and questionnaires were completed for 294 evaluable patients with localized prostate cancer.  Physicians indicated that 55 percent of tests generated a mortality risk score that was either higher or lower than what they expected.  Physicians also indicated that 32 percent of test results would lead to a definite or possible change in treatment plan, with the net effect of shifting patients from more aggressive to more conservative treatment. These data strongly suggest that the Prolaris test can help physicians determine the aggressiveness of prostate cancer and tailor treatment plans for individual patients. A second large prospective clinical utility study called PROCEDE 500 also is underway. An interim analysis of that study showed that physicians would change actual treatment selection in 65 percent of cases after they reviewed the results of the Prolaris test with their patients. Data from PROCEDE 500 will be presented at the ASCO Genitourinary Cancers Symposium in San Francisco on Jan. 30, 2014.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments